Abstract
Healthcare institutions are being asked to immunize an increasingly higher percentage of healthcare providers against influenza each year, with an eventual target of ≥90%. The live-attenuated influenza vaccine (LAIV) is an attractive approach for needle-averse individuals, but concerns have persisted …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
